Developing nanoparticle drug carriers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Developing nanoparticle drug carriers
The development of nanoparticulate drug carriers has followed several routes depending on the final application. Although a wide variety of systems have been designed with their own advantages and limitations, the common goal is to rationalize drug delivery to enhance the bioavailability of the drugs towards targeted diseased cells, promoting the required response while minimizing side-effects. Nanoparticulate drug carriers also represent unique opportunities to get challenging molecules, such as nucleic..


Pharmaceutical Technology Europe
Volume 19, Issue 1

Nanoparticulate drug carriers include a class of particles made of polymers or lipids that — because of their size and chemical composition —permit systemic and local treatment.

In general, these systems are expected to protect a drug from degradation, enhance drug absorption by facilitating diffusion through epithelium, modify the pharmacokinetic and drug tissue distribution profile and/or improve intracellular penetration and distribution.1–3


Table 1 Definition of the different types of nanoparticulate drug carriers and schematic representations.4–18
They can be administered by all possible routes of administration, generally improving both bioavailability and therapeutic efficacy of the carried drug.3 They represent an alternative class of vehicles to liposomes to transport drugs straight to the targeted diseased cells in the body.

Numerous types of nanoparticle drug carriers have been developed (Table 1). The range of applications includes the treatment of all major public health diseases including severe infections and cancer. They are also strongly believed to potentially solve the problem of the in vivo delivery of biomimetic molecules such as nucleic acids, proteins, peptides and very insoluble drugs, which is very difficult by other means (Table 2).

Although several liposomal formulations have been marketed since 1995 — illustrating that nanotechnology can be used to administer toxic drugs such as antifungal and anticancer agents — two new formulations for polymer nanoparticles entered clinical trials recently for cancer therapy.

This article focuses on the development of nanoparticulate drug carriers, highlighting several of the key issues being addressed up to now.


Table 2 Suggested nanoparticulate drug carriers as a function of the physicochemical characteristics of the drug to be administered.3–31





Design

The design of nanoparticulate drug carriers must fulfil the following requirements:

  • Composition must be acceptable for use in human therapy (biodegradable, biocompatible, nontoxic).
  • Size must be suitable for administration to humans by different routes and allow diffusion inside the body to reach the biological target site.
  • The biodistribution should suit the therapeutic target.
  • The carrier must be loaded with the drug and should only release the drug in a controlled manner once the carrier has reached the biological target site.

Composition

As lipids are part of living constituents, they were considered to be suitable chemicals to formulate solid lipid nanoparticles (SLNs) and nanocapsules (LNCs) (Tables 1 and 2).

Synthetic polymers offer an almost infinite array of chemical composition and structure combinations. However, only a few have the requirements that make them useful as nanoparticulate drug carriers.

The prime candidates are polyesters including polylactide (PLA) derivatives and polyepsiloncaprolactone (PCL), polyalkylcyanoacrylate (PACA) and corresponding copolymers with polyethylene glycol (PEG), polysaccharides and polyethylenimine (Tables 1 and 2).

Natural macromolecules including polysaccharides (chitosan, alginate, pectine) were introduced to formulate hydrogel nanoparticles. Research is continuing to find suitable new polymers because polymers can be produced at lower cost than lipids and should be more interesting (economically) based on economic considerations.32 Polyesters of polymalic acid, polyamino acids of polybenzyl-glutamate) and pH- or temperature-sensitive species are growing in popularity.33–37


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here